R&D Strategies at Pharmaceutical Companies 2018
Language:
Japanese
Product Code No:
C59120700
Issued In:
2018/03
#of Pages:
277
Publication Cycle:
Other
Format:
PDF
Geographic Coverage:
Japan
Industry:
Coverage: (Product/service)
R&D Strategies at Pharmaceutical Companies
Research Target:
Pharmaceutical Companies
Research Content:
I R&D Strategies at Pharmaceutical Companies and Actual Status and Perspectives of CRO and SMO
- R&D Strategies at Pharmaceutical Companies
- CRO Market Status and Perspectives
- SMO Market Status and Perspectives
II R&D Strategies at Leading Pharmaceutical Enterprises
- Astellas Pharma Inc.
- AstraZeneca K.K.
- Eisai Co., Ltd.
- MSD K.K. a subsidiary of Merck & Co., Inc.,
- Otsuka Holdings Co., Ltd.
- ONO PHARMACEUTICAL CO., LTD.
- Kyowa Hakko Kirin Co., Ltd.
- GlaxoSmithKline K.K.
- Sanofi K.K.
- SHIONOGI & CO., LTD.
- DAIICHI SANKYO COMPANY, LIMITED
- Sumitomo Dainippon Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited.
- Mitsubishi Tanabe Pharma Corporation
- CHUGAI PHARMACEUTICAL CO., LTD.
- Eli Lilly Japan K.K.
- Boehringer Ingelheim Japan, Inc.
- Novartis Pharma K.K.
- Bayer Yakuhin, Ltd.
- Pfizer Japn, Inc.
III Strategies of CRO/SMO Enterprises
- EPS Holdings, Inc. (EPS Corporation, EP-Mint Co., Ltd.)
- CAC Croit Corporation
- CMIC HOLDINGS Co., Ltd.
- BI Medical, Inc.
- Micron Inc.
- Leading CRO Enterprises: 36 enterprises,
- Leading SMO Enterprises: 35 enterprises